

Martine Bagot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2586230/publications.pdf>

Version: 2024-02-01

102
papers

2,671
citations

186265

28
h-index

206112

48
g-index

103
all docs

103
docs citations

103
times ranked

3470
citing authors

#	ARTICLE	IF	CITATIONS
1	CD24 ^{hi} CD27 ⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 1830-1839.	1.4	144
2	Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 667-670.	1.2	144
3	Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma. <i>Chest</i> , 2016, 149, e133-e136.	0.8	142
4	CD158k/KIR3DL2 Is a New Phenotypic Marker of Sezary Cells: Relevance for the Diagnosis and Follow-Up of Sezary Syndrome. <i>Journal of Investigative Dermatology</i> , 2004, 122, 820-823.	0.7	135
5	CD4 ⁺ cutaneous T-cell lymphoma cells express the p140 killer cell immunoglobulin-like receptor. <i>Blood</i> , 2001, 97, 1388-1391.	1.4	119
6	Therapeutic management of DRESS: A retrospective study of 38 cases. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 246-252.	1.2	110
7	Blood classification and blood response criteria in mycosis fungoides and Sezary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. <i>European Journal of Cancer</i> , 2018, 93, 47-56.	2.8	105
8	Evaluation of Immunophenotypic and Molecular Biomarkers for Sezary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1364-1372.	0.7	78
9	Posaconazole Treatment of Extensive Skin and Nail Dermatophytosis Due to Autosomal Recessive Deficiency of CARD9. <i>JAMA Dermatology</i> , 2015, 151, 192.	4.1	71
10	UBA1 Variations in Neutrophilic Dermatitis Skin Lesions of Patients With VEXAS Syndrome. <i>JAMA Dermatology</i> , 2021, 157, 1349.	4.1	71
11	Significance of circulating T-cell clones in Sezary syndrome. <i>Blood</i> , 2006, 107, 4030-4038.	1.4	69
12	IPH4102, a Humanized KIR3DL2 Antibody with Potent Activity against Cutaneous T-cell Lymphoma. <i>Cancer Research</i> , 2014, 74, 6060-6070.	0.9	65
13	Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients. <i>Cancers</i> , 2020, 12, 2921.	3.7	57
14	CD158k Is a Reliable Marker for Diagnosis of Sezary Syndrome and Reveals an Unprecedented Heterogeneity of Circulating Malignant Cells. <i>Journal of Investigative Dermatology</i> , 2015, 135, 247-257.	0.7	56
15	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. <i>Journal of Investigative Dermatology</i> , 2019, 139, 31-37.	0.7	55
16	CD158K/KIR3DL2 Transcript Detection in Lesional Skin of Patients with Erythroderma Is a Tool for the Diagnosis of Sezary Syndrome. <i>Journal of Investigative Dermatology</i> , 2008, 128, 465-472.	0.7	51
17	Early-Onset Atopic Dermatitis in Children: Which Are the Phenotypes at Risk of Asthma? Results from the ORCA Cohort. <i>PLoS ONE</i> , 2015, 10, e0131369.	2.5	49
18	Killer cell immunoglobulin-like receptor expression delineates in situ Sezary syndrome lymphocytes. <i>Journal of Pathology</i> , 2003, 199, 77-83.	4.5	47

#	ARTICLE	IF	CITATIONS
19	Epigenomic Analysis of SÅ©zary Syndrome Defines Patterns of Aberrant DNA Methylation and Identifies DiagnosticÅMarkers. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1876-1884.	0.7	46
20	Circulating and skin-derived SÅ©zary cells: clonal but with phenotypic plasticity. <i>Blood</i> , 2017, 130, 1468-1471.	1.4	44
21	Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis. <i>Oncologist</i> , 2016, 21, 76-83.	3.7	42
22	Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 281-287.	3.4	42
23	Emergency Department Diagnosis and Management of Skin Diseases With Real-Time Teledermatologic Expertise. <i>JAMA Dermatology</i> , 2014, 150, 743.	4.1	41
24	Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with SÅ©zary Syndrome. <i>Clinical Cancer Research</i> , 2017, 23, 3619-3627.	7.0	41
25	Relationship between cutaneous polyarteritis nodosa (cPAN) and macular lymphocytic arteritis (MLA): Blinded histologic assessment of 35 cPAN cases. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 1013-1020.	1.2	40
26	Triggering CD101 molecule on human cutaneous dendritic cells inhibits T cell proliferation via IL-10 production. <i>European Journal of Immunology</i> , 2000, 30, 3132-3139.	2.9	35
27	In vivo multiphoton imaging of human skin: assessment of topical corticosteroid-induced epidermis atrophy and depigmentation. <i>Journal of Biomedical Optics</i> , 2012, 17, 026009.	2.6	35
28	The High Expression of the microRNA 17â€“92 Cluster and its Paralogs, and the Downregulation of the Target Gene PTEN, Is Associated with Primary Cutaneous B-Cell Lymphoma Progression. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1659-1667.	0.7	34
29	MDA5+ Dermatomyositis Is Associated with Stronger Skin Type I Interferon Transcriptomic Signature with Upregulation of IFN-Î³ Transcript. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1276-1279.e7.	0.7	30
30	Certolizumab pegol â€“ A new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohnâ€™s disease. <i>Journal of Dermatological Treatment</i> , 2016, 27, 67-69.	2.2	29
31	HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma. <i>Blood</i> , 2020, 135, 1058-1061.	1.4	29
32	A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, LegÅType. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1982-1989.	0.7	27
33	Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or Tj ETQq1 1 0.784314 rgBT /Overlo 67, 1197-1208.	4.2	24
34	Next-Generation Sequencing in Myeloid Neoplasm-Associated Sweetâ€™s Syndrome Demonstrates Clonal Relation between Malignant Cells and Skin-Infiltrating Neutrophils. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1873-1876.e5.	0.7	23
35	KIR3DL2 is a coinhibitory receptor on SÅ©zary syndrome malignant T cells that promotes resistance to activation-induced cell death. <i>Blood</i> , 2014, 124, 3330-3332.	1.4	22
36	Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. <i>Onc Immunology</i> , 2016, 5, 1136045.	4.6	22

#	ARTICLE	IF	CITATIONS
37	Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2777-2779.e1.	3.8	20
38	TH cell diversity and response to dupilumab in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 756-759.	2.9	20
39	SÅ©zary syndrome without erythroderma. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 1003-1009.e1.	1.2	19
40	Increased severity and epidermal alterations in persistent versus evanescent skin lesions in adult-onset Still disease. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 969-971.	1.2	18
41	ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. <i>Blood Advances</i> , 2020, 4, 5203-5214.	5.2	18
42	Dominance of an <i>UBA1&/i> mutant clone over a <i>CALR&/i> mutant clone: from essential thrombocytemia to VEXAS.. <i>Haematologica</i> , 2021, 106, 3245-3248.	3.5	18
43	Dermatopulmonary Syndrome Associated With Anti-MDA5 Antibodies After Allogeneic Hematopoietic Stem Cell Transplantation. <i>JAMA Dermatology</i> , 2017, 153, 184.	4.1	17
44	Expression of SÅ©zary Biomarkers in the Blood of Patients with Erythrodermic Mycosis Fungoides. <i>Journal of Investigative Dermatology</i> , 2016, 136, 317-320.	0.7	16
45	A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. <i>European Journal of Dermatology</i> , 2017, 27, 286-294.	0.6	16
46	Chlormethine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience. <i>Dermatology and Therapy</i> , 2021, 11, 1085-1106.	3.0	16
47	Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives. <i>Cancers</i> , 2020, 12, 1497.	3.7	15
48	Clinical, pathological, and molecular features of myelodysplasia cutis. <i>Blood</i> , 2022, 139, 1251-1253.	1.4	15
49	KIR3DL2/CpG ODN Interaction Mediates SÅ©zary Syndrome Malignant T Cell Apoptosis. <i>Journal of Investigative Dermatology</i> , 2015, 135, 229-237.	0.7	14
50	Successful Treatment of Generalized Eruptive Keratoacanthoma of Grzybowski with Acitretin. <i>Dermatology and Therapy</i> , 2019, 9, 383-388.	3.0	14
51	Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in SÅ©zary syndrome. <i>Blood</i> , 2022, 139, 2712-2716.	1.4	14
52	HACE1, a Potential Tumor Suppressor Gene on 6q21, Is Not Involved in Extranodal Natural Killer/T-Cell Lymphoma Pathophysiology. <i>American Journal of Pathology</i> , 2014, 184, 2899-2907.	3.8	13
53	New targeted treatments for cutaneous T-cell Lymphomas. <i>Indian Journal of Dermatology</i> , 2017, 62, 142.	0.3	13
54	IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 691-697.	4.1	12

#	ARTICLE	IF	CITATIONS
55	In vivo multiphoton imaging for noninvasive time course assessment of retinoids effects on human skin. <i>Skin Research and Technology</i> , 2020, 26, 794-803.	1.6	12
56	Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma. <i>Cancer</i> , 2022, 128, 1004-1014.	4.1	12
57	Deficient regulatory B cells in human chronic graft-versus-host disease. <i>OncoImmunology</i> , 2015, 4, e1016707.	4.6	11
58	Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients. <i>European Journal of Dermatology</i> , 2017, 27, 271-274.	0.6	11
59	Cutis laxa associated with monoclonal gammopathy: 14 new cases and review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 945-947.	1.2	10
60	Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas. <i>Cancers</i> , 2020, 12, 2856.	3.7	10
61	Mogamulizumab-induced vitiligo in patients with SÅ©zary syndrome: three cases. <i>European Journal of Dermatology</i> , 2021, 31, 213-216.	0.6	10
62	Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in SÅ©zary syndrome*. <i>British Journal of Dermatology</i> , 2022, 186, 1010-1025.	1.5	10
63	Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chloroquine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides. <i>Dermatology</i> , 2022, 238, 347-357.	2.1	9
64	Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: towards a standardized approach. <i>British Journal of Dermatology</i> , 2022, 187, 21-28.	1.5	9
65	Efficacy of Vinblastine in Primary Cutaneous Anaplastic Large Cell Lymphoma. <i>JAMA Dermatology</i> , 2015, 151, 1030.	4.1	8
66	Cytokine levels in persistent skin lesions of adult-onset Still disease. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 947-949.	1.2	8
67	First case of chancroid in 14 years at the largest STI clinic in Paris, France. <i>International Journal of STD and AIDS</i> , 2016, 27, 805-807.	1.1	7
68	Increased Expression of PLS3 Correlates with Better Outcome in SÅ©zary Syndrome. <i>Journal of Investigative Dermatology</i> , 2017, 137, 754-757.	0.7	7
69	Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries. <i>Cancers</i> , 2022, 14, 145.	3.7	7
70	Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of SÅ©zary Syndrome Patients. <i>Journal of Investigative Dermatology</i> , 2019, 139, 725-728.	0.7	6
71	Suppurative keloids: a complication of severe keloid disease. <i>International Journal of Dermatology</i> , 2021, 60, 1392-1396.	1.0	6
72	Outcome and clinicophenotypical features of acute lymphoblastic leukemia/lymphoblastic lymphoma with cutaneous involvement: A multicenter case series. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1166-1170.	1.2	6

#	ARTICLE	IF	CITATIONS
73	Infliximab in recalcitrant granuloma annulare. <i>International Journal of Dermatology</i> , 2016, 55, 220-222.	1.0	5
74	¹⁸ F-fluorodeoxyglucose-positron emission tomography is more sensitive than computed tomography in initial staging of patients with an anaplastic T-cell lymphoma first presenting in the skin. <i>European Journal of Dermatology</i> , 2017, 27, 496-504.	0.6	5
75	Expansion of Circulating CD49b+LAG3+ Type 1 Regulatory T Cells in Human Chronic Graft-Versus-Host Disease. <i>Journal of Investigative Dermatology</i> , 2021, 141, 193-197.e2.	0.7	4
76	Is mogamulizumab-induced alopecia areata associated with favorable outcomes in SÅ©zary syndrome?. <i>European Journal of Cancer</i> , 2021, 156, S50-S51.	2.8	4
77	ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells. <i>Blood</i> , 2021, 138, 790-790.	1.4	4
78	Head and neck granulomatous rash associated with mogamulizumab mimicking mycosis fungoides. <i>British Journal of Dermatology</i> , 2022, 187, 129-131.	1.5	4
79	Congenital yellow nail syndrome presenting with eyelid lymphedema and fetal hydrops. <i>JAAD Case Reports</i> , 2019, 5, 1010-1012.	0.8	3
80	PAK1-Dependent Antitumor Effect of AAC-11â€™Derived Peptides on SÅ©zary Syndrome Malignant CD4+ T Lymphocytes. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2261-2271.e5.	0.7	3
81	Exploring the role of the skin microenvironment in cutaneous T-cell lymphoma using single cell RNA-sequencing. <i>European Journal of Cancer</i> , 2021, 156, S3-S4.	2.8	3
82	Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIbâ€™IVB mycosis fungoides/SÅ©zary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT). <i>European Journal of Cancer</i> , 2021, 156, S22-S23.	2.8	3
83	Zoon's plasma cell balanitis associated with male genital lichen sclerosus. <i>JAAD Case Reports</i> , 2020, 6, 670-672.	0.8	2
84	Necrotizing cellulitis with multiple abscesses on the leg caused by <i>Serratia marcescens</i> . <i>Cutis</i> , 2016, 97, E8-E12.	0.3	2
85	Authors' Reply. <i>American Journal of Pathology</i> , 2015, 185, 1168.	3.8	1
86	Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1302-1305.	0.7	1
87	Focal Pegylated Liposomal Doxorubicinâ€™Induced Urticarialike Reaction at Cutaneous Transformed SÅ©zary Lesions. <i>JAMA Dermatology</i> , 2017, 153, 475.	4.1	1
88	Increased CD8+CD28- circulating T cells and high blood interferon score characterize the systemic inflammation of amyopathic dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , 2019, 85, 755-758.	1.2	1
89	Uncommon presentation of pigmented paraungual basal cell carcinoma on the first toe treated with total excision. <i>Dermatologic Therapy</i> , 2020, 33, e13289.	1.7	1
90	ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells. <i>European Journal of Cancer</i> , 2021, 156, S23-S24.	2.8	1

#	ARTICLE	IF	CITATIONS
91	Granulomatous rash associated with mogamulizumab mimicking mycosis fungoides: a case series. <i>European Journal of Cancer</i> , 2021, 156, S49.	2.8	1
92	EORTC 21012: Phase II Multicentre Study of Caelyx, a Monotherapy In Patients with Advanced Mycosis Fungoides Stage IIb, Iva and IVb with or without Previous Chemotherapy. <i>Blood</i> , 2010, 116, 2823-2823.	1.4	1
93	Reply to: "The relationship between lymphocytic thrombophilic arteritis and cutaneous polyarteritis nodosa". <i>Journal of the American Academy of Dermatology</i> , 2016, 75, e245-e246.	1.2	0
94	Palliative Radiotherapy for Disfiguring Mycosis Fungoides Lesion: A Key Treatment to Reduce Psychological and Social Impact. <i>Case Reports in Dermatological Medicine</i> , 2018, 2018, 1-4.	0.3	0
95	Asymetric red-blue hypertrophic hand and tenosynovitis due to acrodermatitis chronica atrophicans. <i>Rheumatology</i> , 2019, 58, 655-655.	1.9	0
96	Granular parakeratosis involving the glans of the penis and foreskin. <i>Journal of Dermatology</i> , 2020, 47, e295-e296.	1.2	0
97	Large cell transformation is an independent prognostic factor in Sézary syndrome: a retrospective analysis of 117 cases. <i>European Journal of Cancer</i> , 2021, 156, S25.	2.8	0
98	Acropulpsitis in systemic lupus erythematosus is associated with high type 1 interferon signature. <i>Experimental Dermatology</i> , 2022, 31, 819-820.	2.9	0
99	Quantifying response to various treatments using the revisited blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker. <i>European Journal of Cancer</i> , 2021, 156, S6-S7.	2.8	0
100	The EORTC Cutaneous T-Cell Lymphoma (CTCL) Platform. <i>Blood</i> , 2010, 116, 4896-4896.	1.4	0
101	The importance of dosage for naltrexone treatment in Hailey-Hailey disease. <i>JAAD Case Reports</i> , 2022, 23, 155-157.	0.8	0
102	Clinical characteristics of Mycosis fungoides palmaris et plantaris: two cases and a systematic literature review. <i>European Journal of Dermatology</i> , 2022, 32, 421-423.	0.6	0